10.01.14
Gynesonics Inc. is adding to its executive ranks.
The company has named Richard P. Lanigan as vice president of Global Commercialization effective immediately. He reports directly to President/CEO Christopher M. Owens.
Lanigan, 55, is a San Juan Capistrano, Calif., resident with 23 years of medical device experience that included executive commercial roles and senior management responsibilities on a global basis. Most recently, in 2013, he served as a global commercial operations consultant for Webster, Texas-based IDEV Technologies, a privately held developer of endovascular technologies in the peripheral vascular market that was acquired by Abbott Vascular last year.
"Rich has a wide range of experience in business and clinical development, reimbursement, and global product commercialization, as well as the drive and passion to assist Gyneconics at this stage of our growth," Owens said in a news release. "One of our most immediate goals as a management team is to progress through the next steps in the clinical validation and initial targeted commercialization of our non-surgical VizAblate System for symptomatic fibroids. Rich will take a leadership role in that effort and we are excited to have him on our team."
Before joining IDEV, Lanigan was general manager at Irvine, Calif.--based Synovis Orthopedic & Woundcare Inc., a division of St. Paul, Minn.-based Synovis Life Technologies Inc. (purchased by Baxter International in 2012). Before that, he spent 10 years (2011-2011) in positions of increasing responsibility and ultimately became a corporate officer and acting president at Irvine, Calif.-based Cardiogenesis Corp, which was acquired by CryoLife in 2011.
Lanigan earned a bachelor's degree in business administration from the University of Notre Dame and a masters of science degree in systems management from the University of Southern California. He also served for six years in the U.S. Navy, attaining the rank of lieutenant.
Headquartered in Redwood City, Calif., Gynesonics develops minimally invasive solutions for symptomatic uterine fibroids. Its VizAblate System provides an incision-free approach to symptomatic fibroid treatment, the company claims. In June, VizAblate received CE Mark approval; the device is not approved for sale in the United States. The VizAblate System provides physicians with an incision-free approach for the treatment of symptomatic fibroids, offering an alternative to power morcellation.
The company has named Richard P. Lanigan as vice president of Global Commercialization effective immediately. He reports directly to President/CEO Christopher M. Owens.
Lanigan, 55, is a San Juan Capistrano, Calif., resident with 23 years of medical device experience that included executive commercial roles and senior management responsibilities on a global basis. Most recently, in 2013, he served as a global commercial operations consultant for Webster, Texas-based IDEV Technologies, a privately held developer of endovascular technologies in the peripheral vascular market that was acquired by Abbott Vascular last year.
"Rich has a wide range of experience in business and clinical development, reimbursement, and global product commercialization, as well as the drive and passion to assist Gyneconics at this stage of our growth," Owens said in a news release. "One of our most immediate goals as a management team is to progress through the next steps in the clinical validation and initial targeted commercialization of our non-surgical VizAblate System for symptomatic fibroids. Rich will take a leadership role in that effort and we are excited to have him on our team."
Before joining IDEV, Lanigan was general manager at Irvine, Calif.--based Synovis Orthopedic & Woundcare Inc., a division of St. Paul, Minn.-based Synovis Life Technologies Inc. (purchased by Baxter International in 2012). Before that, he spent 10 years (2011-2011) in positions of increasing responsibility and ultimately became a corporate officer and acting president at Irvine, Calif.-based Cardiogenesis Corp, which was acquired by CryoLife in 2011.
Lanigan earned a bachelor's degree in business administration from the University of Notre Dame and a masters of science degree in systems management from the University of Southern California. He also served for six years in the U.S. Navy, attaining the rank of lieutenant.
Headquartered in Redwood City, Calif., Gynesonics develops minimally invasive solutions for symptomatic uterine fibroids. Its VizAblate System provides an incision-free approach to symptomatic fibroid treatment, the company claims. In June, VizAblate received CE Mark approval; the device is not approved for sale in the United States. The VizAblate System provides physicians with an incision-free approach for the treatment of symptomatic fibroids, offering an alternative to power morcellation.